The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Ryukaikon Submits New Proposal to Improve Drug Distribution Environment
The health ministry’s council for the improvement of ethical drug distribution, known as Ryukaikon, calls for discussions of buyers’ cooperation in promoting single-product, single-price transactions and drug makers’ efforts to share distribution costs in its proposal. In its new proposal,…
To read the full story
Related Article
- JPWA to Establish Taskforce to Discuss Measures for Distribution Problems Cited in Ryukaikon’s New Proposal
December 24, 2015
- Ryukaikon’s New Proposal “Will Greatly Promote the Improvement of Distribution”: JPWA President
September 2, 2015
- Ryukaikon Calls for Elimination of Medical Fee Cut Rule for Low Price Settlement Rates Once Early Price Settlements Are Achieved
September 2, 2015
REGULATORY
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…